Image Place holder

Michael Fradley, MD

 
Specialty: Internal Medicine
Sub Specialty: Clinical Cardiac Electrophysiology, Cardiovascular Disease
Program: Internal Medicine

Overview

Dr. Fradley is an attending cardiologist/electrophysiologist and an Assistant Professor of Medicine at the University of South Florida, Morsani College of Medicine.  He serves as the director of the joint USF-Moffitt Cancer Center Cardio-Oncology Program. He is board certified in Cardiovascular Disease, clinical cardiac electrophysiology, as well as Internal Medicine.    He completed his undergraduate training, with a major in Molecular Biophysics and Biochemistry, at Yale University, where he graduated cum laude with distinction in major. He received his MD degree at the Johns Hopkins School of Medicine, and then remained at Johns Hopkins, completing his residency in Internal Medicine through the Osler Medical Residency Program. He then went on to complete fellowships in both Cardiology and Clinical Cardiac Electrophysiology at Massachusetts General Hospital.   Dr. Fradley's current research interests involve the treatment and prevention of cardiovascular disease in cancer patients and survivors. He has published multiple articles and also served on many committees including the Massachusetts Medical Society Committee on Medical Education and the University of South Florida LCME Faculty Affairs committee. He is also heavily involved in medical education, teaching cardiovascular pathophysiology to second year medical students, and serving as the medical director for the Harvey Simulation course.


Education & Training

Board Certification:

  • Internal Medicine - Clinical Cardiac Electrophysiology
  • Internal Medicine - Cardiovascular Disease

Fellowship:

  • Massachusetts General Hospital, Harvard Medical School - Cardiology
  • Massachusetts General Hospital, Harvard Medical School - Clinical Cardiac Electrophysiology

Residency:

  • Johns Hopkins School of Medicine - Internal Medicine

Medical School:

  • Johns Hopkins School of Medicine - MD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Wang HL, Cousin L, Fradley MG, Donovan KA, Smith B, Szalacha L, Lavoie Smith EM, Buck HG. Exercise Interventions in Cardio-oncology Populations: A Scoping Review of the Literature. J Cardiovasc Nurs. 2020 Mar. Pubmedid: 32195686.
  • Dent SF, Kikuchi R, Kondapalli L, Ismail-Khan R, Brezden-Masley C, Barac A, Fradley M. Optimizing Cardiovascular Health in Patients With Cancer: A Practical Review of Risk Assessment, Monitoring, and Prevention of Cancer Treatment-Related Cardiovascular Toxicity. Am Soc Clin Oncol Educ Book. 2020 Mar.40:1-15. Pubmedid: 32213102.
  • Lee DH, Armanious M, Huang J, Jeong D, Druta M, Fradley MG. Case of pembrolizumab-induced myocarditis presenting as torsades de pointes with safe re-challenge. J Oncol Pharm Pract. 2020 Feb.26(6):1544-1548. Pubmedid: 32089073.
  • Song EY, Venkat P, Fradley M, Frakes JM, Klocksieben F, Fontaine J, Mehta R, Saeed S, Hoffe SE, Pimiento JM. Clinical factors associated with the development of postoperative atrial fibrillation in esophageal cancer patients receiving multimodality therapy before surgery. J Gastrointest Oncol. 2020 Feb.11(1):68-75. Pubmedid: 32175107. Pmcid: PMC7052762.
  • Singh JP, Fradley MG, Kutyifa V. Cardiac Resynchronization Therapy for Chemotherapy-Induced Cardiomyopathy-Reply. Jama. 2020 Apr.323(13):1317. Pubmedid: 32259225.
  • Guha A, Dey AK, Jneid H, Ibarz JP, Addison D, Fradley M. Atrial Fibrillation in the Era of Emerging Cancer Therapies. Eur Heart J. 2019 Sep.40(36):3007-3010. Pubmedid: 31541552. Pmcid: PMC6933869.
  • Lee DH, Chandrashekhar S, Fradley MG. Electrophysiologic Complications in Cancer Patients. Methodist Debakey Cardiovasc J. 2019 Oct.15(4):282-288. Pubmedid: 31988689. Pmcid: PMC6977558.
  • Jeong D, Gladish G, Chitiboi T, Fradley MG, Gage KL, Schiebler ML. MRI in cardio-oncology: A review of cardiac complications in oncologic care. J Magn Reson Imaging. 2019 Nov.50(5):1349-1366. Pubmedid: 31448472.
  • Rhea I, Burgos PH, Fradley MG. Arrhythmogenic Anticancer Drugs in Cardio-Oncology. Cardiol Clin. 2019 Nov.37(4):459-468. Pubmedid: 31587787.
  • Singh JP, Solomon SD, Fradley MG, Barac A, Kremer KA, Beck CA, Brown MW, McNitt S, Schleede S, Zareba W, Goldenberg I, Kutyifa V. Association of Cardiac Resynchronization Therapy With Change in Left Ventricular Ejection Fraction in Patients With Chemotherapy-Induced Cardiomyopathy. Jama. 2019 Nov.322(18):1799-1805. Pubmedid: 31714987. Pmcid: PMC6865289.
  • Lee Chuy K, Oikonomou EK, Postow MA, Callahan MK, Chapman PB, Shoushtari AN, Neilan TG, Fradley MG, Ramanathan LV, Wolchok JD, Steingart RM, Gupta D. Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience. Oncologist. 2019 May.24(5):e196-e197. Pubmedid: 30910868. Pmcid: PMC6516118.
  • Fradley MG. Cardio-Oncology Fellowship Training and Education. Curr Treat Options Cardiovasc Med. 2019 May.21(6):27. Pubmedid: 31104193.
  • Chandrasekhar S, Fradley MG. QT Interval Prolongation Associated With Cytotoxic and Targeted Cancer Therapeutics. CURR TREAT OPTION ON. 2019 May.20(7):55. Pubmedid: 31129799.
  • Guha A, Armanious M, Fradley MG. Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. Trends Cardiovasc Med. 2019 Jan.29(1):29-39. Pubmedid: 29910109.
  • Awadalla M, Golden DLA, Mahmood SS, Alvi RM, Mercaldo ND, Hassan MZO, Banerji D, Rokicki A, Mulligan C, Murphy SPT, Jones-O'Connor M, Cohen JV, Heinzerling LM, Armanious M, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Rizvi MA, Sahni G, Lyon AR, Tocchetti CG, Mercurio V, Thuny F, Ederhy S, Mahmoudi M, Lawrence DP, Groarke JD, Nohria A, Fradley MG, Reynolds KL, Neilan TG. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. J Immunother Cancer. 2019 Feb.7(1):53. Pubmedid: 30795818. Pmcid: PMC6387531.
  • Rhea IB, Lyon AR, Fradley MG. Anticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies. Curr Oncol Rep. 2019 Apr.21(5):45. Pubmedid: 30949848.
  • Lee DH, Fradley MG. Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention. Curr Treat Options Cardiovasc Med. 2018 Mar.20(3):19. Pubmedid: 29508087.
  • Yang EH, Courtney C, Garg V, Fradley MG, Schiller GJ. Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma. Cardiooncology. 2018 Mar.4:2. Pubmedid: 32154003. Pmcid: PMC7048019.
  • Medeiros BC, Possick J, Fradley M. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. Blood Rev. 2018 Jul.32(4):289-299. Pubmedid: 29454474.
  • Buck HG, Hupcey J, Wang HL, Fradley M, Donovan KA, Watach A. Heart Failure Self-care Within the Context of Patient and Informal Caregiver Dyadic Engagement: A Mixed Methods Study. J Cardiovasc Nurs. 2018 Jul.33(4):384-391. Pubmedid: 29601368.
  • Armanious MA, Mohammadi H, Khodor S, Oliver DE, Johnstone PA, Fradley MG. Cardiovascular effects of radiation therapy. Curr Prob Cancer. 2018 Jul.42(4):433-442. Pubmedid: 30006103.
  • Fradley MG, Groarke JD, Laubach J, Alsina M, Lenihan DJ, Cornell RF, Maglio M, Shain KH, Richardson PG, Moslehi J. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. Brit J Haematol. 2018 Jan.180(2):271-275. Pubmedid: 29048105.
  • Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018 Apr.71(16):1755-1764. Pubmedid: 29567210. Pmcid: PMC6196725.
  • Armanious MA, Mishra S, Fradley MG. Electrophysiologic Toxicity of Chemoradiation. Curr Oncol Rep. 2018 Apr.20(6):45. Pubmedid: 29644475.
  • Fradley MG, Brown AC, Shields B, Viganego F, Damrongwatanasuk R, Patel AA, Hartlage G, Roper N, Jaunese J, Roy L, Ismail-Khan R. Developing a Comprehensive Cardio-Oncology Program at a Cancer Institute: The Moffitt Cancer Center Experience. Oncol Rev. 2017 Jun.11(2):340. Pubmedid: 28781723. Pmcid: PMC5523022.
  • Sajjad M, Fradley M, Sun W, Kim J, Zhao X, Pal T, Ismail-Khan R. An Exploratory Study to Determine Whether BRCA1 and BRCA2 Mutation Carriers Have Higher Risk of Cardiac Toxicity. Genes (Basel). 2017 Feb.8(2). Pubmedid: 28157161. Pmcid: PMC5333048.
  • Fradley MG, Neilan TG. Cardiovascular Outcomes in Anthracycline-Related Cardiomyopathy: When a p Value of >0.05 Is a Good Outcome!. JACC Clin Electrophysiol. 2017 Feb.3(2):151-153. Pubmedid: 29759387.
  • Damrongwatanasuk R, Fradley MG. Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia. Curr Treat Options Cardiovasc Med. 2017 Apr.19(4):24. Pubmedid: 28316033.
  • Jeong D, Patel A, Francois CJ, Gage KL, Fradley MG. Cardiac Magnetic Resonance Imaging in Oncology. Cancer Control. 2017 Apr.24(2):147-160. Pubmedid: 28441369.
  • Fradley MG. The evolving field of cardio-oncology: beyond anthracyclines and heart failure. Eur Heart J. 2016 Sep.37(36):2740-2742. Pubmedid: 27694540.
  • Diwadkar S, Patel AA, Fradley MG. Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity. Case Rep Cardiol. 2016 Mar.2016:3456287. Pubmedid: 26942019. Pmcid: PMC4749759.
  • Lenihan DJ, Hartlage G, DeCara J, Blaes A, Finet JE, Lyon AR, Cornell F, Moslehi J, Oliviera G, Murtagh G, Fisch M, Zeevi G, Iakobishvili Z, Witteles R, Patel A, Harrison E, Fradley M, Curigliano G, Lenneman CG, Magalhaes A, Krone R, Porter C, Parasher S, Dent S, Douglas P, Carver J. Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty. J Card Fail. 2016 Jun.22(6):465-471. Pubmedid: 27038642.
  • Fradley MG, Moslehi J. QT Prolongation and Oncology Drug Development. Card Electrophysiol Clin. 2015 Jun.7(2):341-355. Pubmedid: 26002398.
  • Pinilla-Ibarz J, Sweet K, Emole J, Fradley M. Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. Anticancer Res. 2015 Dec.35(12):6355-6364. Pubmedid: 26637844.
  • Fradley MG, Barrett CD, Clark JR, Francis SA. Ventricular fibrillation cardiac arrest due to 5-fluorouracil cardiotoxicity. Tex Heart Inst J. 2013.40(4):472-476. Pubmedid: 24082383. Pmcid: PMC3783134.
  • Coglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, McCabe EL, Cheng S, Fradley MG, Kretschman D, Gao W, O'Connor G, Wang TJ, Januzzi JL. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem. 2012 Dec.58(12):1673-1681. Pubmedid: 23065477. Pmcid: PMC3557515.
  • Fradley MG, Drachman DE. A Rare Case of Acute Myocardial Infarction due to Coronary Artery Dissection and Heparin-Induced Thrombocytopenia. Case Rep Med. 2012 Aug.2012:196020. Pubmedid: 22719771. Pmcid: PMC3375156.
  • Fradley MG, Thakuria JV, Collins AB, Moore SA, Stone JR. Direct tissue evaluation via immunofluorescence: in the diagnosis of hereditary transthyretin cardiac amyloidosis. Tex Heart Inst J. 2012.39(1):71-75. Pubmedid: 22412233. Pmcid: PMC3298917.
  • Fradley MG, Larson MG, Cheng S, McCabe E, Coglianese E, Shah RV, Levy D, Vasan RS, Wang TJ. Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study). Am J Cardiol. 2011 Nov.108(9):1341-1345. Pubmedid: 21864812. Pmcid: PMC3209520.
  • Kittleson MM, Bead V, Fradley M, St John ME, Champion HC, Kasper EK, Russell SD, Wittstein IS, Hare JM. Elevated uric acid levels predict allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transpl. 2007 May.26(5):498-503. Pubmedid: 17449420.
  • Fradley M, Liu J, Atta MG. Primary aldosteronism with HIV infection: important considerations when using the aldosterone:renin ratio to screen this unique population. Am J Ther. 2005 Jul.12(4):368-374. Pubmedid: 16041202.
  • Fradley MG, Damrongwatanasuk R, Chandrasekhar S, Alomar M, Kip KE, Sarnaik AA. Cardiovascular Toxicity and Mortality Associated With Adoptive Cell Therapy and Tumor-infiltrating Lymphocytes for Advanced Stage Melanoma. J Immunother. 44(2):86-89. Pubmedid: 33044384.

Patient Comments
Overall Satisfaction
0

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments